A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
Juan Vera, insider at Marker Therapeutics

Juan Vera Insider Information

For the past 12 years, Juan F. Vera has worked extensively on developing novel T cell therapies and optimizing manufacturing processes for clinical applications at the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine. In collaboration with Wilson Wolf Manufacturing, he has been instrumental in the design and testing of the G-Rex® cell culture platform and pioneered its use for the large-scale production of T cells. Dr. Vera has extensive expertise in developing and streamlining therapeutic candidates from the research bench to the cGMP facility while ensuring robust production and scalability. Dr. Vera has previously collaborated with Celgene and Bluebird Bio in developing novel CAR T cell therapies. He has also been the recipient of different prestigious awards including the Idea Development Award from the Department of Defense and Mentored Research Scholar Award from the American Cancer Society. Dr. Vera attained his M.D. from the University El Bosque in Bogota, Colombia.

What is Juan Vera's net worth?

The estimated net worth of Juan Vera is at least $1.02 million as of March 16th, 2021. Dr. Vera owns 2,564,487 shares of Marker Therapeutics stock worth more than $1,024,256 as of August 15th. This net worth evaluation does not reflect any other assets that Dr. Vera may own. Learn More about Juan Vera's net worth.

How old is Juan Vera?

Dr. Vera is currently 42 years old. There are 4 older executives and no younger executives at Marker Therapeutics. The oldest executive at Marker Therapeutics is Mr. Michael J. Loiacono, Chief Accounting Officer, Treasurer & Sec., who is 56 years old. Learn More on Juan Vera's age.

How do I contact Juan Vera?

The corporate mailing address for Dr. Vera and other Marker Therapeutics executives is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. Marker Therapeutics can also be reached via phone at (713) 400-6400 and via email at [email protected] Learn More on Juan Vera's contact information.

Has Juan Vera been buying or selling shares of Marker Therapeutics?

Juan Vera has not been actively trading shares of Marker Therapeutics during the past quarter. Most recently, on Tuesday, March 16th, Juan Vera bought 571,428 shares of Marker Therapeutics stock. The stock was acquired at an average cost of $1.75 per share, with a total value of $999,999.00. Following the completion of the transaction, the insider now directly owns 2,564,487 shares of the company's stock, valued at $4,487,852.25. Learn More on Juan Vera's trading history.

Juan Vera Insider Trading History at Marker Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2021Buy571,428$1.75$999,999.002,564,487View SEC Filing Icon  
See Full Table

Juan Vera Buying and Selling Activity at Marker Therapeutics

This chart shows Juan Vera's buying and selling at Marker Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Marker Therapeutics Company Overview

Marker Therapeutics logo
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Read More

Today's Range

Now: $0.40
Low: $0.39
High: $0.40

50 Day Range

MA: $0.34
Low: $0.26
High: $0.56

2 Week Range

Now: $0.40
Low: $0.25
High: $2.05


384,887 shs

Average Volume

1,080,709 shs

Market Capitalization

$33.39 million

P/E Ratio


Dividend Yield



The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!